open access

Vol 15, No 6 (2019)
Review paper
Published online: 2020-01-10
Get Citation

Molecular targeted therapy of patients with non-small-cell lung cancer

Katarzyna Stencel, Daria Świniuch, Rodryg Ramlau
DOI: 10.5603/OCP.2019.0025
·
Oncol Clin Pract 2019;15(6):289-296.

open access

Vol 15, No 6 (2019)
REVIEW ARTICLES
Published online: 2020-01-10

Abstract

Lung cancer is the most common cause of cancer-related death both in men and women in Poland and worldwide. Patients diagnosed with non-small-cell lung cancer (NSCLC) of non-squamous and not otherwise specified (NOS) histologies may benefit from targeted therapies, because these types of cancers most often harbor molecular disturbances such as activating EGFR gene mutations, rearrangements of ALK, ROS1 or NTRK genes and BRAF gene mutation. These disorders are a positive predictors of the response to treatment with tyrosine kinase inhibitors. The necessity of molecular tests in patients with advanced NSCLC to be performed prior to qualification for systemic chemotherapy should be emphasized and — in the case of positive results — the use of targeted therapy in the first line treatment.

Abstract

Lung cancer is the most common cause of cancer-related death both in men and women in Poland and worldwide. Patients diagnosed with non-small-cell lung cancer (NSCLC) of non-squamous and not otherwise specified (NOS) histologies may benefit from targeted therapies, because these types of cancers most often harbor molecular disturbances such as activating EGFR gene mutations, rearrangements of ALK, ROS1 or NTRK genes and BRAF gene mutation. These disorders are a positive predictors of the response to treatment with tyrosine kinase inhibitors. The necessity of molecular tests in patients with advanced NSCLC to be performed prior to qualification for systemic chemotherapy should be emphasized and — in the case of positive results — the use of targeted therapy in the first line treatment.

Get Citation

Keywords

non-small-cell lung cancer, EGFR, ALK, ROS1, BRAF, targeted therapy

About this article
Title

Molecular targeted therapy of patients with non-small-cell lung cancer

Journal

Oncology in Clinical Practice

Issue

Vol 15, No 6 (2019)

Article type

Review paper

Pages

289-296

Published online

2020-01-10

DOI

10.5603/OCP.2019.0025

Bibliographic record

Oncol Clin Pract 2019;15(6):289-296.

Keywords

non-small-cell lung cancer
EGFR
ALK
ROS1
BRAF
targeted therapy

Authors

Katarzyna Stencel
Daria Świniuch
Rodryg Ramlau

References (33)
  1. http://onkologia.org.pl/raporty/.
  2. Lindeman N, Cagle P, Aisner D, et al. Updated molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for Study of Lung Cancer, and the Association for Molecular Pathology. Journal of Thoracic Oncology. 2018; 13: 323–358.
  3. Sharma S, Bell D, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer. 2007; 7(3): 169–181.
  4. https://ec.europa.eu/health/documents/community-register/2017/20170329137415/anx_137415_pl.pdf.
  5. Mok T, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. NEJM. 2009; 361(10): 947–957.
  6. Douillard JY, Ostoros G, Cobo M, et al. First-line gefitinib in caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer. 2014; 110(1): 55–62.
  7. https://ec.europa.eu/health/documents/community-register/2005/200509199999/anx_9999_pl.pdf.
  8. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12(8): 735–742.
  9. Rosell R, Carcereny E, Gervais R, et al. Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3): 239–246.
  10. https://www.ema.europa.eu/documents/product-information/giotrif-epar-product-information_pl.pdf.
  11. Sequist LV, Yang JCH, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31(27): 3327–3334.
  12. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15(2): 213–222.
  13. Yang JH, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The Lancet Oncology. 2015; 16(2): 141–151.
  14. Schuler M, Wu YL, Hirsh V, et al. First-Line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016; 11(3): 380–390.
  15. Yang JCH, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015; 16(7): 830–838.
  16. www.fda.gov.
  17. Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2017; 18(11): 1454–1466.
  18. Mok TS, Cheng Y, Zhou X, et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018; 36(22): 2244–2250.
  19. Maemondo M, Inoue A, Kobayashi K, et al. North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362(25): 2380–2388.
  20. Sequist L, Martins R, Grunberg S, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. Journal of Clinical Oncology, 2008:10. ; 26(20): 3472.
  21. Santarpia M, Liguori A, Karachaliou N, et al. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer: Targets and Therapy. 2017; 8: 109–125.
  22. Wu YL, Ahn MJ, Garassino MC, et al. AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFRT 790M-positive lung cancer. N Engl J Med. 2017; 376(7): 629–640.
  23. https://ec.europa.eu/health/documents/community-register/2016/20160202133956/anx_133956_pl.pdf.
  24. Soria JC, Ohe Y, Vansteenkiste J, et al. FLAURA Investigators. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(2): 113–125.
  25. https://www.gov.pl/web/zdrowie/choroby-onkologiczne.
  26. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368(25): 2385–2394.
  27. Solomon BJ, Kim DW, Wu YL, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. J Clin Oncol. 2018; 36(22): 2251–2258.
  28. Solomon B, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New England Journal of Medicine. 2014; 371(23): 2167–2177.
  29. Hanna N, Johnson D, Temin S, et al. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. J Clin Oncol. 2017; 35(30): 3484–3515.
  30. Peters S, Camidge DR, Shaw AT, et al. ALEX Trial Investigators. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017; 377(9): 829–838.
  31. Camidge D, Peters S, Mok T, et al. Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) versus crizotinib (CZ) in untreated advanced ALK+ NSCLC. ASCO 2018 Annual Meeting.
  32. Novello S, Mazières J, Oh IJ, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018; 29(6): 1409–1416.
  33. Shaw AT, Ou SHI, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 371(21): 1963–1971.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl